MAVIRET 50 mg/20 mg, coated granules in a sachet 28 sachets
Active ingredients: Glecaprevir, Pibrentasvir
Commercialized according to BDPMDispensing in France: Prescription only
Coated granules28 sachetsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MAVIRET 50 mg/20 mg, granulés enrobés en sachet
- Pharmaceutical form
- granulés enrobé
- Route of administration
- orale
- Presentation description
- 28 sachet(s) polytéréphtalate (PET) aluminium polyéthylène
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 12 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62685529CIP73023608CIP133400930236086Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLÉCAPRÉVIRgranulés | 50 mg · un sachet | SA |
| PIBRENTASVIRgranulés | 20 mg · un sachet | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.